Piramal Pharma

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (PPL) (NSE: PPLPHARMA | BSE: 543635), offering end-to-end development and manufacturing solutions across the drug life cycle. It serves customers through a globally integrated network of facilities in North America, Europe, and Asia, with services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms, as well as specialized services such as highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. Piramal Pharma Limited offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries, and includes Piramal Pharma Solutions, Piramal Critical Care, and the India Consumer Healthcare business.

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (PPL) (NSE: PPLPHARMA | BSE: 543635), offering end-to-end development and manufacturing solutions across the drug life cycle. It serves customers through a globally integrated network of facilities in North America, Europe, and Asia. Piramal Pharma Limited offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries, and includes Piramal Pharma Solutions, Piramal Critical Care, and the India Consumer Healthcare business. The history page lists milestones including: 1988 Acquired Nicholas Laboratories, marking entry into pharmaceuticals; 1991 Commissioned first formulation plant in Pithampur, Madhya Pradesh; 1992 Renamed Nicholas Laboratories Ltd. to Nicholas Piramal India Ltd.; 1993 Entered into a joint venture with Allergan; 1993 Acquired Roche India's domestic formulations and nutrition products/services business; 1994 Acquired Boehringer Mannheim's formulation plant in Mahad; 1995 Acquired the bulk drug division of Sumitra Pharmaceutical and Chemical Ltd., Hyderabad; 1996 Boehringer Mannheim fully acquired; 2000 Began collaborative research in gene technology with the Centre for Biochemical Technology; 2002 Acquired ICI Pharma; 2003 Acquired Global Bulk Drugs; 2005 Acquired Avecia Pharmaceuticals; 2006 Acquired Morpeth facility from Pfizer; 2009 Greenfield investment in Ahmedabad (PPDS); 2011 Acquired Oxygen Bio Research, a CRO based in Ahmedabad; 2012 Piramal Healthcare renamed to Piramal Enterprises, integrating pharma, Financial Services (FS), and new businesses created/acquired – FS and DRG; 2015 Acquired Kentucky-based CDMO Coldstream Laboratories Inc.; 2016 Acquired Ash Stevens Inc., a U.S.-based developer specializing in high-potency APIs; 2020 Acquired solid oral dosage drug product facility in Sellersville, Pennsylvania, from G&W Laboratories Inc.; 2020 Becomes a subsidiary of Piramal Enterprises and receives strategic growth investment by Carlyle; 2021 Acquired Hemmo Pharmaceuticals, a leading Indian manufacturer of peptide APIs; 2021 Acquired a mino...

Your CDMO Partner for the Entire Drug Lifecycle

• 2026-08-18

  Piramal Pharma completes acquisition of 40.67% incremental stake in Yapan Bio[5]Piramal Pharma完成对Yapan Bio额外40.67%股权的收购thehindu.com

  Reported: 2026-08-19

  Piramal Pharma Ltd. completed the acquisition of an incremental 40.67% stake in Hyderabad-based CDMO Yapan Bio Private Limited for an aggregate cash consideration of ₹76 crore ($7.95M), raising its ownership to 74% and making Yapan Bio a subsidiary.

• 2026-08-18

  Piramal Pharma completes acquisition of controlling stake in Yapan Bio[6]Piramal Pharma完成对Yapan Bio控股权的收购leaderpost.com

  Reported: 2026-08-18

  Piramal Pharma Ltd. completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited for an aggregate cash consideration of ₹76 crore ($7.95M USD), bringing its ownership to 74% and making Yapan Bio a subsidiary.

• 2021-06-23

  Piramal Pharma completes acquisition of Hemmo Pharmaceuticals[7]Piramal Pharma完成对Hemmo Pharmaceuticals的收购economictimes.indiatimes.com

  Reported: 2021-06-23

  Piramal Pharma completed its acquisition of Hemmo Pharmaceuticals, according to Piramal Enterprises.

• 2020-06-27

  Carlyle acquires a 20% stake in Piramal Pharma[8]凯雷收购 Piramal Pharma 20% 股权business-standard.com

  Reported: 2020-06-27

  Carlyle acquired a 20% stake in Piramal Pharma for US$490 million (nearly Rs 3,700 crore). The deal was expected to close in 2020, with the final equity investment amount dependent on net debt, exchange rates and performance against pre-agreed conditions.

1. 1Piramal Pharma Solutions | Global CDMO Pharma Company for Pharma Innovators and Biotechspiramalpharmasolutions.com
2. 2Piramal Pharma Solutions History | Milestones & Legacypiramalpharmasolutions.com
3. 3About Piramal Pharma Solution | Global Innovative Pharma Companypiramalpharmasolutions.com
4. 4Integrated Drug Discovery Services | Forward Integrated with Drug Substance and Formulationspiramalpharmasolutions.com
5. 5Piramal Pharma完成对Yapan Bio额外40.67%股权的收购thehindu.com
6. 6Piramal Pharma完成对Yapan Bio控股权的收购leaderpost.com
7. 7Piramal Pharma完成对Hemmo Pharmaceuticals的收购economictimes.indiatimes.com
8. 8凯雷收购 Piramal Pharma 20% 股权business-standard.com
9. 9Piramal sells 20% stake in pharma business to US based Carlyle for Rs 3,700 crore - BusinessTodaybusinesstoday.in